.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,681,585

« Back to Dashboard

Details for Patent: 5,681,585

Title: Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
Abstract:A stabilized solid controlled release dosage form having a coating derived from an aqueous dispersion of ethylcellulose is obtained by overcoating a substrate including a therapeutically active with an aqueous dispersion of ethylcellulose and then curing the coated substrate at a temperature and relative humidity elevated to a suitable level above ambient conditions until the coated dosage form attains a stabilized dissolution profile substantially unaffected by exposure to storage conditions of elevated temperature and/or elevated relative humidity.
Inventor(s): Oshlack; Benjamin (New York, NY), Chasin; Mark (Manalapan, NJ), Pedi, Jr.; Frank (Yorktown Heights, NY)
Assignee: Euro-Celtique, S.A. (Luxembourg, LU)
Filing Date:Jun 20, 1996
Application Number:08/667,052
Claims:1. An oral controlled release pharmaceutical formulation comprising

a plurality of inert beads coated with an opioid analgesic, said inert beads incorporated into said formulation in an mount sufficient to provide a desired therapeutic effect,

a barrier layer of over said core containing said opioid analgesic, said barrier layer comprising hydroxypropylmethylcelllose,

a controlled release layer over said barrier layer comprising an aqueous dispersion of plasticized ethylcellulose in an amount sufficient to obtain a controlled release of said opioid analgesic when said formulation is exposed to an environmental fluid, said coated substrate being cured to the temperature greater film than the glass transition temperature of the aqueous dispersion of the plasticized ethylcellulose for at least about 24 hours.

2. The formulation of claim 1, wherein said substrate is coated with said controlled release layer to a weight gain from about 2 to about 25%.

3. The formulation of claim 1, wherein a plurality of said coated, cured beads are placed in a capsule in an amount sufficient to provide an effective controlled release dose when contacted by an aqueous solution.

4. The formulation of claim 1, further comprising a second barrier layer over said controlled release layer, said second barrier layer comprising hydroxypropylmethylcellulose.

5. The formulation of claim 1, wherein said controlled release coating further comprises a release-modifying agent in an amount effective to modify the rate of release of said opioid analgesic from said cured, coated substrate.

6. A method for obtaining an oral controlled release formulation of an opioid analgesic, comprising:

coating pharmaceutically acceptable inert beads with an opioid analgesic;

thereafter coating said beads with a barrier layer comprising hydroxypropylmethylcellulose;

thereafter applying a controlled release layer onto said beads, said controlled release layer comprising a sufficient amount of a plasticized ethylcellulose to obtain a predetermined controlled release of said opioid analgesic when said coated beads are exposed to an environmental fluid, said plasticized ethylcellulose being applied to said beads as an aqueous dispersion;

curing said controlled release layered beads at a temperature greater than the glass transition temperature of the aqueous dispersion of plasticized ethylcellulose for at least 24 hours, and

thereafter optionally applying a second barrier coating to said beads.

7. The method of claim 6, further comprising preparing said substrate for oral administration by placing a sufficient quantity of cured coated beads into a gelatin capsule.

8. The method of claim 6, wherein said barrier agent comprises hydroxypropylmethylcellulose.

9. The method of claim 6, further comprising applying said controlled release coating onto said beads to a weight gain from about 2 to about 25%.

10. The method of claim 6, further comprising including a release-modifying agent in said controlled release coating an amount effective to modify the rate of release of said active agent from said cured, coated beads.

11. A solid controlled release formulation, comprising a plurality of pharmaceutically acceptable inert beads coated with an opioid analgesic, said formulation comprising an amount of said beads sufficient to provide a desired effect when said formulation is orally administered to a patient, said beads coated with said opioid analgesic being overcoated with a barrier layer comprising hydroxypropylmethylcellulose, said barrier coated beads being coated with a controlled release layer of plasticized ethylcellulose in an mount sufficient to obtain a controlled release of said opioid analgesic when said formulation is exposed to a gastrointestinal fluid, said ethylcellulose being applied to said beads as an aqueous dispersion, said coated beads being cured at a temperature greater than the glass transition temperature of the aqueous dispersion of plasticized ethylcellulose for at least about 24 hours, to cause individual ethylcellulose particles in said coating to coalesce and to gradually slow the release of said opioid analgesic when said formulation is exposed to aqueous fluid, until an endpoint is reached at which said cured coated substrate, when subjected to in-vitro dissolution, releases said active agent in mounts which do not vary at any time point along the dissolution curve by more than about 20% of the total mount of active agent released, when compared to the in-vitro dissolution of said coated beads prior to outing.

12. The formulation of claim 11, wherein said cured, coated beads provide the same rate of release immediately after curing to said endpoint, and after subsequent exposure to accelerated storage conditions of one month at a temperature of 37.degree. C. and at a relative humidity of 80%.

13. The formulation of claim 11, wherein said cured, coated beads provide the same rate of release immediately after curing to said endpoint, and after subsequent exposure to accelerated storage conditions of one month at a temperature of 40.degree. C. and at a relative humidity of 75%.

14. The formulation of claim 11, wherein said controlled release coating is applied on said barrier coated beads to a weight gain from about 2% to about 25%.

15. The formulation of claim 11, wherein a plurality of said coated, cured beads are placed in a capsule in an amount sufficient to provide an effective controlled release dose when contacted by an aqueous solution.

16. The formulation of claim 11, wherein said cured, coated formulation when administered orally provides effective blood levels of said systemically active opioid analgesic for about 24 hours.

17. The formulation of claim 11, which includes a controlled release coating sufficient to obtain a controlled release of said opioid analgesic when measured by the U.S. patent Paddle Method at 100 rpm at 900 ml aqueous buffer (pH between 1.6 and 7.2) at 37.degree. C. from about 12.5% to about 42.5% (by wt) opioid analgesic released after 1 hours, from about 25% to about 55% (by wt) opioid analgesic released after 2 hours, from about 45% to about 75% (by wt) opioid analgesic released after 4 hours and from about 55% to about 85% (by wt) opioid analgesic released after 8 hours.

18. The formulation of claim 11, wherein said controlled release coating further comprises a release-modifying agent in an amount effective to modify the rate of release of said opioid analgesic from said cured, coated substrate.

19. The formulation of claim 11, which provides therapeutically effective blood levels of said systemically active opioid analgesic when administered orally for about 12 hours.

20. The formulation of claim 11, further comprising a second barrier layer overcoated on said controlled release coating.

21. The formulation of claim 20, wherein said second barrier layer comprises hydroxypropylmethylcellulose.

22. The formulation of claim 1, wherein said coated substrate is cured for a time from about 24 to about 72 hours.

23. The formulation of claim 1, which includes a controlled release coating sufficient to obtain a controlled release of said opioid analgesic when measured by the U.S. patent Paddle Method at 100 rpm at 900 ml aqueous buffer (pH between 1.6 and 7.2) at 37.degree. C. from about 12.5% to about 42.5% (by wt) opioid analgesic released after 1 hour, from about 25% to about 55% (by wt) opioid analgesic released after 2 hours, from about 45% to about 75% (by wt) opioid analgesic released after 4 hours and from about 55% to about 85% (by wt) opioid analgesic released after 8 hours.

24. The method of claim 6, wherein said curing is conducted for a time from about 24 to about 72 hours.

25. The formulation of claim 11, wherein said coated beads are cured for a time from about 24 to about 72 hours.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc